UNAUDITED FINANCIAL RESULT FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025
Awaiting price reaction for this filing.
Citurgia Biochemicals reported zero revenue from operations and no other income for Q2 FY26 (ended 30 Sep 2025) as well as H1 FY26. The company posted a net loss of ₹11.20 lakhs in the quarter and ₹19.59 lakhs for the half year, broadly in line with the ₹13.95 lakh loss in the year-ago quarter. Total expenses were only administrative in nature — employee costs (₹7.40L), depreciation (₹11.10L H1), and other expenses (₹1.09L H1). The balance sheet shows negative net worth of ₹733.49 lakhs due to accumulated losses of ₹3,625.40 lakhs against equity capital of ₹2,641.91 lakhs. Cash flow from operations was negative at ₹11.47 lakhs for H1, while overall cash position edged up marginally to ₹14.17 lakhs. Auditor G.P. Keshri & Associates issued a clean (unqualified) limited review report with no qualifications or emphasis of matter.
With zero revenue, continuous losses, and negative net worth, the company appears financially distressed and dependent on borrowings (₹687L) and shareholder support to stay afloat — a classic going concern risk for shareholders.